DP

Diadema Partners Portfolio holdings

AUM $144M
1-Year Est. Return 22.15%
This Quarter Est. Return
1 Year Est. Return
+22.15%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$144M
AUM Growth
-$17.3M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
128
New
Increased
Reduced
Closed

Top Buys

1
+$13.8M
2
+$6.13M
3
+$5.86M
4
ASND icon
Ascendis Pharma
ASND
+$5.48M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.56M

Top Sells

1
+$14.5M
2
+$11.5M
3
+$11.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.7M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.9M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
101
Intellia Therapeutics
NTLA
$1.05B
– –
0
NUVL icon
102
Nuvalent
NUVL
$8.3B
– –
-5,000
NVAX icon
103
Novavax
NVAX
$1.11B
– –
0
OCUL icon
104
Ocular Therapeutix
OCUL
$2.44B
– –
0
OLMA icon
105
Olema Pharmaceuticals
OLMA
$2.18B
– –
-253,657
PBYI icon
106
Puma Biotechnology
PBYI
$262M
– –
0
PFE icon
107
Pfizer
PFE
$145B
– –
0
PHAT icon
108
Phathom Pharmaceuticals
PHAT
$1.04B
– –
-40,294
PRAX icon
109
Praxis Precision Medicines
PRAX
$4.66B
– –
0
PRTA icon
110
Prothena Corp
PRTA
$601M
– –
0
QURE icon
111
uniQure
QURE
$1.59B
– –
0
RCEL icon
112
Avita Medical
RCEL
$107M
– –
0
REPL icon
113
Replimune Group
REPL
$810M
– –
-32,483
RXRX icon
114
Recursion Pharmaceuticals
RXRX
$2.43B
– –
0
SAVA icon
115
Cassava Sciences
SAVA
$150M
– –
0
SCPH
116
DELISTED
scPharmaceuticals
SCPH
– –
-217,623
SLS icon
117
SELLAS Life Sciences
SLS
$219M
– –
0
SMMT icon
118
Summit Therapeutics
SMMT
$13.7B
– –
-932
SPRY icon
119
ARS Pharmaceuticals
SPRY
$944M
– –
0
SPY icon
120
SPDR S&P 500 ETF Trust
SPY
$700B
– –
0
SRRK icon
121
Scholar Rock
SRRK
$4.44B
– –
-62,926
TNGX icon
122
Tango Therapeutics
TNGX
$1.29B
– –
0
TVTX icon
123
Travere Therapeutics
TVTX
$3.12B
– –
0
SKYE icon
124
Skye Bioscience
SKYE
$39.1M
– –
0
ATYR
125
aTyr Pharma
ATYR
$75.5M
– –
0
2 3 4
5
6